REDWOOD CITY, Calif. - Corcept Therapeutics (NASDAQ:CORT) Incorporated (NASDAQ: CORT), a company specializing in the development of treatments for severe metabolic, oncologic, and endocrinologic disorders, has reported promising results from a Phase 3 long-term extension study of relacorilant for the treatment of hypercortisolism, commonly known as Cushing’s syndrome. The findings were presented at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.
The study involved 116 patients who had previously participated in Corcept’s Phase 2 or Phase 3 trials. Over a treatment duration of up to six years, relacorilant demonstrated clinically meaningful improvements in cardiometabolic health, including sustained reductions in blood pressure and maintenance of glycemic control and body weight. The medication was also reported to be well-tolerated by the patients.
At the 24-month mark, statistically significant reductions in mean systolic and diastolic blood pressure were observed. These results were particularly notable in patients who had been switched to a placebo during a randomized withdrawal phase but then resumed relacorilant treatment.
Dr. Richard Auchus, who presented the data, emphasized the significance of the long-term improvements in blood pressure and the maintenance of cardiometabolic health, highlighting the drug's potential as a treatment for hypercortisolism without the toxicities associated with current therapies. This development has caught analysts' attention, with InvestingPro data showing price targets ranging from $67 to $80 per share, reflecting confidence in the company's pipeline potential.
Corcept plans to submit a New Drug Application (NDA) for relacorilant based on these findings, along with data from earlier studies. The company believes that relacorilant's efficacy and safety profile could establish it as a new standard of care for patients with hypercortisolism.
Hypercortisolism, or Cushing’s syndrome, is a condition characterized by excessive cortisol levels, which can lead to serious health issues like hypertension, obesity, and type 2 diabetes. Current treatment options can have significant side effects, underscoring the need for more effective and tolerable therapies.
Relacorilant is designed to selectively modulate cortisol's effects by binding to the glucocorticoid receptor without affecting other hormone receptors. It has been granted orphan drug designation in the United States and the European Union for the treatment of Cushing’s syndrome.
The information reported is based on a press release statement from Corcept Therapeutics.
In other recent news, Corcept Therapeutics Incorporated has made significant strides in its clinical and financial performance. The company's Phase 4 CATALYST study achieved its primary endpoint, showing that Korlym significantly improved blood sugar levels in patients with hypercortisolism and hard-to-control type 2 diabetes. On the other hand, the Phase 2 DAZALS study of dazucorilant did not meet its primary endpoint for patients with ALS, but survival data has led to the continuation of an open-label extension study.
Corcept Therapeutics also reported a robust increase in third-quarter revenue to $182.5 million, a 48% year-over-year rise, and a net income of $47.2 million. As a result, the company raised its full-year revenue guidance for 2024 to between $675 million and $700 million. Despite facing litigation with Teva Pharmaceuticals over a generic version of Korlym, the company is preparing to submit a New Drug Application for relacorilant, a treatment for Cushing's syndrome, backed by positive results from the GRACE and GRADIENT studies.
These recent developments highlight Corcept Therapeutics' commitment to addressing severe health conditions and its strong financial health, as analyzed by InvestingPro. In the coming years, the company aims to become a $3 billion business, reflecting its optimism about its trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.